Storage Instructions To preserve the structural integrity of the peptide blend, the lyophilized compound should be stored at 20C or lower in a controlled laboratory environment
Research Significance
Urgent medical attention: Call 999 or go to A&E immediately if you experience: Severe allergic reactions (difficulty breathing, facial swelling, widespread rash) Symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back, often with nausea and vomiting) Signs of severe hypoglycaemia if taking other diabetes medications (confusion, loss of consciousness) Contact your GP, diabetes specialist or NHS 111 promptly if you experience: Signs of infection at the injection site (increasing pain, redness, swelling, warmth, or discharge) Persistent severe nausea, vomiting, or diarrhoea, especially with signs of dehydration Symptoms of gallbladder problems (sudden pain in upper abdomen, especially on the right side, fever, yellowing of skin/eyes) Visual changes, particularly if you have diabetic retinopathy Moderate hypoglycaemia symptoms (sweating, tremor, rapid heartbeat, hunger) Seek advice before your next appointment if: You are pregnant, planning pregnancy, or breastfeeding You need guidance on managing your medication during illness You have questions about side effects or dosage You're unsure about injection technique with your pre-filled pen Medication sourcing and safety: In the UK, tirzepatide should only be obtained through legitimate, regulated channels such as NHS prescriptions or registered private healthcare providers
Lilly PACKAGE LABEL - Mounjaro Multi-Dose Vial - 5 mg/0.6 mL Dose (20 mg/2.4 mL [8.33 mg/mL]) Rx Only NDC 0002-4103-11 Mounjaro (tirzepatide) injection 20 mg/2.4 mL (8.33 mg/mL) ATTENTION: Contains 4 doses of 5 mg/0.6 mL 2.4 mL MULTI-DOSE VIAL For Subcutaneous Use Needles and Syringes are not included Dispense enclosed Medication Guide to each patient
